HBA’s own Kelly H. Zou was a featured invited speaker in the Real World Evidence Track at the 2019 World Congress Meeting Value-Based Health Care Congress held on 21-22 October in Arlington, VA. Kelly is vice president and head of medical analytics and insights, R&D and medical, Upjohn Division, Pfizer Inc. She is our current HBA NY and NJ regional treasurer. Kelly is a Fellow of the American Statistical Association and an Accredited Professional Statistician. She has published extensively on clinical and methodological topics. Kelly earned both her MA and PhD degrees in statistics from the University of Rochester and completed her joint postdoctoral fellowship trainings in health care policy and radiology at Harvard Medical School. Previously, she was associate professor at Harvard Medical School, associate director at Barclays Capital and senior director in statistics and real-world evidence and methods and algorithms group lead at Pfizer Inc. She has authored over 140 articles and several statistical monographs. Kelly has been on several professional journal and magazine editorial boards and is the incoming chair-elect and past secretary of the Health Policy Statistics Section; chair and past vice-chair of the Statistical Partnerships among Academe, Industry, and Government Committee; and chair of the Committee of Presidents of Statistical Societies Awards Committee.
The HBA is proud and lucky to have Kelly serve on the HBA NY/NJ chapter board.
As value-based healthcare continues to transform and changes to regulations around the world provide pathways to accelerated drug approvals, there is a timely opportunity to leverage data science and analytics to establish cross-stakeholder partnerships, improve health outcomes and differentiate a product and brand in the market.
The Real-World Data and Evidence Track showcased successful strategies for optimizing data strategies, usages and analytics across the product lifecycle, highlight applications, methodologies for data access and integration, analytical tools, and strategies for implementing end-to-end evidence management.
- Utilize real-world evidence to demonstrate both clinical and cost-effectiveness of your product to payers and providers;
- Explore payer, health system and regulatory perspectives to create cross-stakeholder partnerships to harness first-in-class in science;
- Leverage real-world evidence to optimize clinical development and accelerate drug discovery;
- Discover digital applications to optimize evidence generation.